

Member FINRA/SIPC

Toll-Free: 866-928-0928 ♦ www.DawsonJames.com ♦ 101 North Federal Highway - Suite 600 ♦ Boca Raton, FL 33432

Anavex Life Sciences Corp. (NASDAQ/AVXL)

January 17, 2024

BUY Rated: Phase 2 Trial of ANAVEX3-71 for the Treatment of Schizophrenia – This is Something New!

Jason Kolbert
Managing Director & Senior Analyst
jkolbert@dawsonjames.com

Anavex Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia. This is planned as a placebo-controlled Phase 2 trial (and cleared by the FDA), set to begin in Q2 2024. The trial is to include Schizophrenia validated clinical outcomes PANSS and EEG/ERP biomarkers. The trial will study positive, negative, and cognitive domains of Schizophrenia based on ANAVEX®3-71's ability to activate both SIGMAR1 and M1 muscarinic receptors synergistically. 3-71 is not in our model and is not reflected as part of our valuation.

Investment Highlights:


What is ANAVEX®3-71 (formerly AF710B)? It is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator with agonistic effects. This novel mechanism of action offers the potential to treat all symptom domains (positive, negative, and cognitive) of schizophrenia without the side effects of standard-of-care antipsychotics. The selective nature of ANAVEX®3-71's dual synergistic mechanism of action has previously demonstrated long-lasting, pro-cognitive effects and behavioral improvements in animal models of neurodegenerative diseases. ANAVEX®3-71 has also previously demonstrated the ability to prevent cognitive decline in an animal model of Alzheimer's disease.

Study Design: The trial is planned as a placebo-controlled Phase 2 study designed in two parts. One is to explore multiple ascending doses in individuals with schizophrenia followed by a 28-day treatment period in a larger cohort. The study will utilize standard clinical outcome measures for schizophrenia including the Positive and Negative Symptoms Scale (PANSS) and novel electrophysiological biomarkers identified by the ERP Biomarker Qualification Consortium for use in schizophrenia clinical trials.

Valuation. Our valuation is based on our therapeutic models and associated assumptions projected to 2030. Our model assumes multiple financial raises, so our share count is based on a projected, fully diluted out-year basis. Given the early nature of the company and its dependence on clinical trial outcomes in the CNS space, we apply a probability of success (50%) in our models. On top of this, we also add a 30% risk rate in our free cash flow to the Firm (FCFF), our discounted EPS (dEPS), and sum-of-the-parts (SOP) models. We equal weight and average these metrics and then round to the nearest whole number to derive our price target.

Risks to our thesis include: (1) commercial; (2) regulatory; (3) clinical; (4) market share; (5) financial; (6) investment; and (7) intellectual property.

Current Price \$5.98
Price Target \$39.00



Stock Data		
52-Week Range	\$4.90	\$11.93
Shares Outstanding (mil.)	82.1	
Market Capitalization (mil.)	\$491	
Enterprise Value (mil.)	\$340	
Debt to Capital	0%	
Book Value/Share	\$0.56	
Price/Book	3.8	
Average Three Months Trading Volume (K)	900	
Insider Ownership	3.1%	
Institutional Ownership	30.7%	
Short interest (mil.)	24.5%	
Dividend / Yield	\$0.00/0.0%	




Exhibit 1. Income Statement (\$ '000)

Anavex Life Sciences Corp																
Anavex: YE Sept 30	2019A	2020A	2021A	2022A	1Q23A	2Q23A	3Q23A	4Q23E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
Revenue																
Anavex2-73 AD U.S.		-	-	-	-	-	-	-	-	-	-	996,342	1,332,252	1,067,282	1,244,145	1,348,343
Anavex2-73 AD ROW												1,235,807	1,285,239	1,103,163	1,350,272	1,606,824
Anavex2-73 Rett's Syndrome										28,192	71,890	586,623	747,945	915,484	933,794	952,470
Anavex2-73 Parkinson's Dementia PDD												177,649	241,602	369,651	439,885	480,732
Total Product Revenues										28,192	71,890	2,996,421	3,607,037	3,455,581	3,968,096	4,388,368
% Chg																
% Sequential Growth																
Milestones																
% Sequential Growth																
Total Revenues (\$000)										28,192	71,890	2,996,421	3,607,037	3,455,581	3,968,096	4,388,368
Expenses																
Cost of Goods Sold (10%)												223,215	261,749	217,045	259,442	295,517
Accounting and Audit Fees																
Amortization and depreciation	2	2	2	2	0	0	0	0	2	2	2	2	2	2	2	2
Bank charges and interest																
Consulting Fees																
Insurance																
Investor relations																
Legal fees																
Management fees																
Office and miscellaneous expense																
Registration and filing fees																
Rent and administration																
Research and Development	22,260	25,232	32,267	41,326	11,307	11,307	10,061	10,111	42,785	32,600	26,473	21,498	17,457	14,176	11,512	9,349
Salaries and wages																
Travel																
Website design and maintenance																
General and Administrative	6,847	5,857	9,205	13,320	2,883	2,883	2,592	3,000	11,357	27,500	45,000	45,450	45,905	46,364	46,827	47,295
Operating expenses	31,287	31,088	41,474	54,647	14,189	14,190	12,653	13,112	54,144	60,101	71,474	290,164	325,112	277,586	317,783	352,162
Oper. Inc. (Loss)	(31,287)	(31,088)	(41,474)	(54,647)	(14,189)	(14,190)	(12,653)	(13,112)	(54,144)	(31,909)	416	2,706,257	3,281,925	3,177,995	3,650,314	4,036,206
Oper Margin	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	0	1	1	1	1	1
Other income (expense)	2,466															
Research and Development incentive				682												
Interest and financing fees	207			(25)												
Accretion of debt discount	116									(25)	(25)	(25)	(25)	(25)	(25)	(25)
Change in fair value of derivative liability	(151)															
Debt conversion expense	(42)															
Loss on settlement of accounts payable																
Loss on extinguishment of debt																
Foreign exchange gain (loss)				(733)												
Financing related charges and adjustments																
Other non-operating income																
Non-operating Income (expense)	2,894	-	2,129	(75)	-	-	-	-	-	(25)	(25)	(25)	(25)	(25)	(25)	(25)
Financial Income, Net																
Financial Expenses, Net		4,830	4,555	(1,132)	(1,132)	(1,132)	2,242	(1,132)	(1,132)							
Pretax Income	(28,393)	(26,258)	(36,918)	(54,722)	(13,057)	(13,057)	(10,211)	(13,112)	(54,144)	(31,934)	391	2,706,232	3,281,900	3,177,970	3,650,289	4,036,181
Pretax Margin	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM
Income Tax Benefit (Provision)	(82)	(23)	(155)	(319)	(50)	(50)	(64)	(1,311)	(1,475)	(5,748)	113	893,056	1,181,484	1,239,408	1,423,613	1,574,110
Tax Rate	0%	0%	1%	1%	10%	10%	10%	10%	3%	18%	29%	30%	31%	31%	31%	31%
GAAP Net Income (loss)	(28,475)	(26,280)	(37,074)	(50,068)	(13,107)	(13,107)	(10,147)	(11,801)	(48,162)	(26,186)	277	1,813,175	2,100,416	1,938,561	2,226,676	2,462,070
Net Margin	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	0.00	0.61	0.58	0.56	0.56	0.56
GAAP-EPS	(0.65)	(0.45)	(0.53)	(0.65)	(0.17)	(0.17)	(0.12)	(0.14)	(0.60)	(0.31)	0.00	19.73	21.95	19.47	21.49	22.84
Non GAAP EPS (dil)	(0.65)	(0.45)	(0.53)	(0.65)	(0.17)	(0.17)	(0.12)	(0.14)	(0.60)	(0.31)	0.00	19.73	21.95	19.47	21.49	22.84
Wgtd Avg Shrs (Bas)	48,906	58,195	69,869	77,278	78,304	78,304	81,973	82,055	80,159	82,260	82,590	82,921	83,253	83,586	83,921	84,257
Wgtd Avg Shrs (Dil)	48,906	58,195	69,869	77,278	78,304	78,304	81,973	82,793	80,344	84,883	88,330	91,917	95,649	99,532	103,574	107,779

Source: Dawson James estimates, company reports

Risk Analysis

Clinical Trial Risk. Anavex is dependent on the outcome of multiple clinical trials. The failure rates associated with disease conditions such as Alzheimer's are historically very high.

Commercial Risk. Anavex hopes to compete in the CNS markets, which have traditionally been dominated by large pharma and biotechnology companies with deep pockets (funding and resources), which may make it difficult for Anavex to compete unless the molecule is deemed to be truly differentiated.

Financial Risk. Anavex is likely to require additional capital raises before the company can be self-sustaining. There can be no guarantees that the company will be able to raise the needed capital.

Investment Risk. Anavex is a small capital company, which can translate into high volatility and risk for investors. The company has no revenues and is dependent on the clinical progress of its therapeutics.

Intellectual Property. Anavex may face I.P. challenges, forcing the company to defend its patents or itself against claims that the company is infringing on other patents. We do know that the lead product is protected by a composition of matter patent to 2033.


Market Share Risk. The central nervous system (CNS) market is competitive and tends to be dominated by large pharma and large well-established biotechnology companies.

Regulatory Risk. Anavex, even with good clinical data, could face extensive delays and other regulatory setbacks.

Companies mentioned in this report:

Important Disclosures:

Price Chart:



Price target and rating changes over the past three years:

- Initiated – Buy – July 24, 2019 – Price Target \$16.00
- Update – Buy – July 31, 2019 – Price Target \$16.00
- Update – Buy – August 7, 2019 – Price Target \$16.00
- Update – Buy – September 5, 2019 – Price Target \$16.00
- Update – Buy – September 17, 2019 – Price Target \$16.00
- Update – Buy – October 24, 2019 – Price Target \$16.00
- Update – Buy – December 2, 2019 – Price Target \$16.00
- Update – Buy – December 4, 2019 – Price Target \$16.00
- Update – Buy – February 4, 2020 – Price Target \$16.00
- Update – Buy – February 7, 2020 – Price Target \$16.00
- Update – Buy – May 8, 2020 – Price Target \$16.00

Update – Buy – May 22, 2020 – Price Target \$16.00
Update – Buy – June 16, 2020 – Price Target \$16.00
Update – Buy – July 1, 2020 – Price Target \$16.00
Update – Buy – October 15, 2020 – Price Target \$16.00
Update – Buy – November 6, 2020 – Price Target \$16.00
Update – Buy – December 15, 2020 – Price Target \$16.00
Price Target Change – Buy – February 19, 2021 – Price Target \$16.0 to \$19.00
Update – Buy – April 5, 2021 – Price Target \$19.00
Update – Buy – April 12, 2021 – Price Target \$19.00
Update – Buy – May 19, 2021 – Price Target \$19.00
Update – Buy – June 8, 2021 – Price Target \$19.00
Price Target Change – Buy – June 21, 2021 – Price Target \$35.00
Update – Buy – June 28, 2021 – Price Target \$35.00
Update – Buy – October 27, 2021 – Price Target \$35.00
Update – Buy – November 24, 2021 – Price Target \$35.00
Update – Buy – January 11, 2022 – Price Target \$35.00
Update – Buy – February 1, 2022 – Price Target \$35.00
Update – Buy – February 4, 2022 – Price Target \$35.00
Update – Buy – February 10, 2022 – Price Target \$39.00
Update – Buy – June 15, 2022 – Price Target \$39.00
Update – Buy – August 2, 2022 – Price Target \$39.00
Update – Buy – August 9, 2022 – Price Target \$39.00
Update – Buy – October 18, 2022 – Price Target \$39.00
Update – Buy – November 8, 2022 – Price Target \$39.00
Update – Buy – November 28, 2022 – Price Target \$39.00
Update – Buy – November 30, 2022 – Price Target \$39.00
Update – Buy – December 5, 2022 – Price Target \$39.00
Update – Buy – February 2, 2023 – Price Target \$39.00
Update – Buy – February 7, 2023 – Price Target \$39.00
Update – Buy – March 9, 2023 – Price Target \$39.00
Update – Buy – March 30, 2023 – Price Target \$39.00
Update – Buy – May 9, 2023 – Price Target \$39.00
Update – Buy – June 6, 2023 – Price Target \$39.00
Update – Buy – June 13, 2023 – Price Target \$39.00
Update – Buy – June 28, 2023 – Price Target \$39.00
Update – Buy – August 8, 2023 – Price Target \$39.00
Update – Buy – September 15, 2023 – Price Target \$39.00
Update – Buy – October 27, 2023 – Price Target \$39.00
Update – Buy – November 21, 2023 – Price Target \$39.00
Update – Buy – November 28, 2023 – Price Target \$39.00
Update – Buy – December 19, 2023 – Price Target \$39.00
Update – Buy – December 21, 2023 – Price Target \$39.00
Update – Buy – January 3, 2024 – Price Target \$39.00
Update – Buy – January 17, 2024 – Price Target \$39.00

Dawson James Securities, Inc. (the "Firm") is a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC").

The Firm does not make a market in the securities of the subject company(s). The Firm has NOT engaged in investment banking relationships with AVXL in the prior twelve months, as a manager or co-manager of a public offering and has NOT received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject company(s). The Firm has not received other compensation from the subject company(s) in the last 12 months for services unrelated to managing or co-managing of a public offering.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of December 14, 2023, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts or

employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the company(s) subject to this report. The Firm may affect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

Information about risks can be found in the "RISK ANALYSIS" section of this report.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.

Rating Definitions:

- 1) **Buy:** The analyst believes the price of the stock will appreciate and produce a total return of at least 20% over the next 12-18 months;
- 2) **Neutral:** The analyst believes the price of the stock is fairly valued for the next 12-18 months;
- 3) **Sell:** The analyst believes the price of the stock will decline by at least 20% over the next 12-18 months and should be sold.

The following chart reflects the range of current research report ratings for all companies followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

Current as of 14-Dec-23

	Company Coverage		Investment Banking	
Ratings Distribution	# of Companies	% of Total	# of Companies	% of Totals
Market Outperform (Buy)	21	61.76%	4	11.80%
Market Perform (Neutral)	13	38.24%	2	5.90%
Market Underperform (Sell)	0	0%	0	0.00%
Total	34	100%	6	17.70%

Analyst Certification:

The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.